Live Feeds
● LIVE Updated 2h ago · 18 sources tracked

AbbVie Revenue Rises on Strength in Immunology, Neuroscience

AbbVie posted third-quarter worldwide revenue of $17.4 billion, marking a 10.3% year-on-year increase driven primarily by its immunology and neuroscience portfolios. Chief Executive Officer Rob Michael noted that nine key products delivered double-digit growth during the quarter. The pharmaceutical giant reported GAAP diluted earnings per share of $2.37 and adjusted diluted earnings per share of $3.82. In response to the strong performance, leadership raised the company's full-year adjusted earnings per share guidance to a range of $13.95 to $13.99, up from the previous forecast of $13.76 to $13.96.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (18)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ AbbVie reported third-quarter worldwide revenue of $17.4 billion, a 10.3% increase year on year.
  • ✓ The company posted third-quarter GAAP diluted earnings per share of $2.37 and adjusted diluted earnings per share of $3.82.
  • ✓ AbbVie raised its full-year adjusted earnings per share guidance to $13.95 to $13.99.
  • ✓ CEO Rob Michael stated that nine key products delivered double-digit growth in the third quarter.
🛡️ Source Corroboration: 18 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

AbbVie reported third-quarter 2026 financial results that exceeded expectations and lifted its full-year earnings guidance.

Live updates

  1. AbbVie Raises Annual Forecast Following Q3 Revenue Growth

    AbbVie posted third-quarter worldwide revenue of $17.4 billion, marking a 10.3% year-on-year increase driven primarily by its immunology and neuroscience portfolios. Chief Executive Officer Rob Michael noted that nine key products delivered double-digit growth during the quarter. The pharmaceutical giant reported GAAP diluted earnings per share of $2.37 and adjusted diluted earnings per share of $3.82. In response to the strong performance, leadership raised the company's full-year adjusted earnings per share guidance to a range of $13.95 to $13.99, up from the previous forecast of $13.76 to $13.96.

    Why it matters

    The stronger-than-expected third-quarter financial results arrive as AbbVie seeks to sustain momentum across its core therapeutic divisions, relying heavily on products like Skyrizi and Rinvoq to offset older patent losses. Entering the earnings release, the stock had climbed roughly 21% over the preceding three months, establishing a reputation as a high-multiple pharmaceutical giant. Analysts continue to evaluate the long-term sustainability of the immunology division and the trajectory of the company's growth pipeline.

    What is confirmed

    • AbbVie reported third-quarter worldwide revenue of $17.4 billion, a 10.3% increase year on year.
    • The company posted third-quarter GAAP diluted earnings per share of $2.37 and adjusted diluted earnings per share of $3.82.
    • AbbVie raised its full-year adjusted earnings per share guidance to $13.95 to $13.99.
    • CEO Rob Michael stated that nine key products delivered double-digit growth in the third quarter.

    Still unconfirmed

    • Some market sources reported that AbbVie shares fell 2.47% to $287.60 during Monday's session.
    • Trading view sources indicated that AbbVie stock hit an all-time high following investor enthusiasm.

    What to watch next

    • Quarterly performance of Skyrizi and Rinvoq sales figures
    • Future adjustments to AbbVie full-year guidance metrics
    Sources used for this update (21)
    1. finance.yahoo.com — Yahoo Finance - Stock Market Live, Quotes, Business & Finance News
    2. www.marketscreener.com — Global Stocks Fall on Higher Oil Prices, AI Pullback | MarketScreener
    3. www.marketbeat.com — Top Biotech Stocks To Research - October 14th | MarketBeat
    4. Reuters — AbbVie lifts annual profit forecast as immunology drugs continue to fuel growth
    5. WSJ — AbbVie Revenue Rises on Strength in Immunology, Neuroscience
    6. Yahoo Finance — Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings
    7. TradingView — LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm Today
    8. Fierce Pharma — As Skyrizi and Rinvoq dominate AbbVie's Q3, analysts ask what's next
    9. The Motley Fool — Is AbbVie a Buy After Its Latest Earnings Report?
    10. Yahoo Finance — AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates
    11. KTVB — AbbVie: Q3 Earnings Snapshot
    12. www.marketscreener.com — AbbVie 3Q Revenue Rises on Strength in Immunology, Neuroscience
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community